Similar to our findings, increased NRG-1 secretion has been attributed to gefitinib resistant breast cancer cells [44], and recently NRG-1 rendered cells insensitive to trastuzumab-DM1 [45]. The gene discussed is NRG1; the disease is breast carcinoma.